Edit

eGenesis

https://www.egenesisbio.com/

Last activity: 03.11.2025

Active

Categories: AlternativeBioTechDevelopmentEngineeringHumanLifePlatformProductTechnology

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation.

eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.

Likes

Followers

1.36K

Followers

5.04K

Mentions

Location: United States, Massachusetts, Cambridge

Employees: 51-200

Total raised: $454M

Founded date: 2015

Twitter

Investors 7

Date	Name	Website
-	Altium Cap...	altiumcap....
-	Alta Partn...	altapartne...
-	Khosla Ven...	khoslavent...
-	T1D Fund	t1dfund.or...
-	Wellington...	wellington...
-	HBM Partne...	hbmpartner...
-	SymBiosis	symbiosis....

Funding Rounds 4

Date	Series	Amount	Investors
04.09.2024	Series B	$191M	-
02.03.2021	Series C	$125M	-
07.11.2019	Series B	$100M	-
16.03.2017	Series A	$38M	-

Mentions in press and media 26

Date	Title	Description
03.11.2025	First clinical trial of pig kidney transplants gets underway	By LAURAN NEERGAARD, AP Medical Writer WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives. Related Articles Federal judge won’t block Colorado prescription ...
15.09.2025	Flagship's Lila Sciences lands $235M to expand AI-powered autonomous research labs	Flagship Pioneering’s Lila Sciences has landed a substantial $235 million series A as it looks to exceed the current limits of the drug discovery process through automation. The round, which more than doubles the AI outfit’s March debut of ...
12.05.2025	HepQuant Demonstrates New Advancements in Management of Patients with Acute Liver Failure Dependent on Extracorporeal Liver Cross-Circulation (ELC)	Simultaneous Measurement of Human and Porcine Liver Function at Each Element of an ELC System. HepQuant Demonstrates New Advancements in Management of Patients with Acute Liver Failure Dependent on Extracorporeal Liver Cross-Circulation (EL...
24.02.2025	OrganOx Closes $142M Equity Financing	OrganOx, an Oxford, UK-based organ medical technology company, raised $142M in equity funding. The round was led by new investor HealthQuest Capital with participation from existing investors BGF and Lauxera Capital Partners, along with add...
30.01.2025	The Future of Transplants: Pig Organs and Genetic Diversity	In a world where the demand for organ transplants outstrips supply, a glimmer of hope emerges from an unexpected source: pigs. The story of a woman named Looney, who received a genetically modified pig kidney, marks a significant milestone ...
27.01.2025	Health \| The only person in the world with a functioning pig organ is thriving after a record 2 months	“We’re quite optimistic that this is going to continue to work and work well for, you know, a significant period of time,” he said. Scientists are genetically altering pigs so their organs are more humanlike to address a severe shortage of ...
04.09.2024	eGenesis Raises $191M in Series B Funding	eGenesis, a Cambridge, MA-based biotechnology company developing human-compatible engineered organs to address the global organ shortage, raised $191M in Series B funding. The round was led by Lux Capital, with participation from existing i...
04.09.2024	Natco Pharma’s Canadian arm invests $8 million in eGenesis	Natco Pharma’s wholly-owned Canadian subsidiary, Natco Pharma (Canada) Inc., invested $8 million in the US-based biotechnology company, eGenesis, Inc. “We are excited to get involved with eGenesis, Inc. with respect to their pioneering work...
04.09.2024	eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant Shortages	eGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with partici...
01.04.2024	Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать...	Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн...
11.10.2023	In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years	Scientists at a Massachusetts-based biotechnology company and their academic research partners reported Wednesday that an engineered breed of miniature pig containing up to 69 genetic changes produced kidneys that functioned well in monkeys...
29.04.2021	High Turnover? Here's How To Find (And Address) The Root Cause	An employee comes to human resources to put in their resignation. Just as you've found someone to fill their now-open position, another employee gives their notice as well. Soon, it becomes clear that your company is facing a turnover probl...
02.03.2021	eGenesis Announces $125 Million Series C Financing	Proceeds will advance two lead xenotransplantation programs in kidney failure and type 1 diabetes into first-in-human studies.
02.03.2021	eGenesis Raises $125M in Series C Financing	eGenesis, a Cambridge, Mass.-based gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, completed a $125m Series C financing. Backers included Farallon Capital Management, Polaris Partners, HBM...
28.04.2020	15 Ways HR Can Help New Managers Overcome The Challenges Of Their Role	New managers, whether hired from the outside or promoted from within, are often faced with multiple challenges in their roles, ranging from getting used to their new duties and responsibilities to gaining the trust of their team and ensurin...
07.11.2019	A Biotech Company Gets $100M For The Future of Pig-To-Human Transplants	29 Shares Email Facebook Twitter LinkedIn There are nearly 2 million people on the organ transplant waiting list around the world. Some of the original CRISPR – a modern, advanced gene editing tool – engineers think that pig organs could be...
07.11.2019	eGenesis raises $100M to render pig organs safe for transplant through genetic editing	By using gene editing to unlock new sources of safe and human-compatible organs, eGenesis hopes to cut down the long and tragic delays faced by those waiting for a potential transplant, including more than 113,000 people in the U.S. alone. ...
07.11.2019	eGenesis Raises $100M in Series B Financing	eGenesis, a Cambridge, Mass.-based biotechnology company utilizing gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, completed a $100m Series B financing. The r...
07.11.2019	eGenesis raises $100M to render pig organs safe for transplant through genetic editing	By using gene editing to unlock new sources of safe and human-compatible organs, eGenesis hopes to cut down the long and tragic delays faced by those waiting for a potential transplant, including more than 113,000 people in the U.S. alone. ...
07.11.2019	Wellington Partners participates in $100 Million Series B financing at eGenesis	eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, today announced the successful completion of a $100 m...
07.11.2019	A Biotech Company Gets $100M For The Future of Pig-To-Human Transplants	23 Shares Email Facebook Twitter LinkedIn There are nearly 2 million people on the organ transplant waiting list around the world. Some of the original CRISPR – a modern, advanced gene editing tool – engineers think that pig organs could be...
06.07.2017	Report: Alphabet venture arm GV, Khosla Ventures claim top spots in healthcare investment ranks	Two investors that embrace this hybrid approach to healthcare investment also topped the category for investment volume — Alphabet’s investment arm, GV, and Khosla Ventures with seven deals apiece. GV led or took part in healthcare investme...
16.03.2017	Term Sheet — Thursday, March 16	THE CRAFT BEER BATTLE MOVES TO CHINA Good morning, Term Sheet readers. Today’s column (tipple?) is from Fortune editor Matt Heimer. Enjoy. Paid Content What you need to know about growing cyberattacks From ExtraHop In the wider beer world, ...
16.03.2017	eGenesis Raises $38M Series A Funding	eGenesis, a Cambridge, MA-based biotechnology company focused on utilizing genome editing technology to enable xenotransplantation* as a routine medical procedure, raised a $38m Series A financing. The round was co-led by Biomatics Capital ...
-	EGenesis	“At eGenesis, we envision a world in which no one dies waiting for an organ transplant.”
-	Report: Alphabet venture arm GV, Khosla Ventures claim top spots in healthcare investment ranks	Healthcare investments hit $3.8 billion in the second quarter of 2017, marking a spike in these deals and a milestone for the healthcare industry in general, according to StartUp Health’s half year report. The trend of fewer deals but with ...

eGenesis

Investors 7

Funding Rounds 4

Mentions in press and media 26

Reviews 0